AP601
Investigational
Phase 1Active
Key Facts
About AP Biosciences
AP Biosciences leverages a bispecific antibody platform to advance oncology and ophthalmology candidates through late‑stage clinical trials.
View full company profileAbout AP Biosciences
AP Biosciences leverages a bispecific antibody platform to advance oncology and ophthalmology candidates through late‑stage clinical trials.
View full company profileTherapeutic Areas
Other Investigational Drugs
| Drug | Company | Phase |
|---|---|---|
| AP505/B1962 | AP Biosciences | Phase 2 |
| AP203 | AP Biosciences | Phase 1 |
| AP201 | AP Biosciences | Phase 1 |